Risorius, a Korean startup innovating personalized and quantified technologies in psychiatry and neurology, has secured follow-on investment after its 2023 seed round. The latest round was led by KAIST Venture Investment Holdings(KVI), with participation from MYSC, ZD Ventures, Impact Foundation, and Hyun-joon Kim, former CEO of Vuno. The investment amount remains undisclosed.

Founded in July 2023 by CEO Sang-yoon Bae, Risorius aims to provide clear guidance for prescribing neurological and psychiatric medications. The core team, including the CEO, consists of current students and graduates from Seoul National University College of Medicine.

This investment recognizes Risorius’s efforts in developing an AI-based platform for personalized drug effect prediction and quantified technologies for neurological disorders. Risorius leverages AI to analyze brainwave data, offering a fresh perspective in the field.

Jun-hyun Ahn, a director at KVI, said, “With one in four South Koreans experiencing mental health issues, the rapid rise in depression and anxiety patients highlights the challenge of timely, appropriate medication, prolonging treatment and causing significant personal and societal losses. Risorius, with its exceptional research capabilities and proprietary datasets from collaborations with major domestic hospitals, is expected to provide clear solutions.” This was the rationale behind the investment.

Sang-yoon Bae, CEO of Risorius, stated, “We aim to significantly improve patient outcomes by reducing ambiguity in neurology and psychiatry through technology development. With this funding, we will intensify R&D while expanding our market presence through collaborations with key players like pharmaceutical companies and insurers.”

Since its inception, Risorius has swiftly advanced its business strategy and technology depth through joint research with hospitals, open innovation with large corporations, government support programs, and accelerators.

With this investment, Risorius plans to build data for AI training and maximize its technological edge through expanded hospital partnerships. It is also preparing to commercialize its brainwave-based product, currently in the productization phase.